Prices delayed by at least 15 minutes | Print


Novartis AG (NVS)

Equity
Sell: $95.05|Buy: $98.44|Change: 0.85 (0.89%)

Open 

$96.28


Previous close 

$95.88


Trade high 

$97.2


Volume 

1,524,700


Year high 

$108.78


Year low 

$89.81


Dividend yield 

3.94%


Market capitalisation 

$197.72 bn


P/E ratio 

23.39


ISIN 

US66987V1098


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Dividends

PreviousLatest
Record date10/03/202308/03/2024
Ex-dividend date09/03/202307/03/2024
Payment date20/03/2023Invalid date
Amount$3.4986993$3.7772131

Performance 31/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Novartis AG+ 0.89
More...

Company profile

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.